Compound having formula I: and pharmaceutically acceptable salts thereof, wherein: X is selected from S or O; R 1 is selected from the group consisting of: -OR 5 wherein R 5 is selected from H; C 1 -C 4 alkyl, trifluoromethanesulfonyl, benzyl, (trifluoromethyl)benzyl, (halo)benzyl, (trifluoromethyl)benzoyl, N-benzylcarbamoyl, cyclohexyloxyacetoyl substituted with at least one C 1 -C 3 alkyl group, (C 1 -C 3 alkoxy)methyl, C 1 -C 3 alkanoyl and CH 2 CH 2 NHR 6, wherein R 6 is selected from H and (furan-2-yl)methyl; -NHR 7 wherein R 7 is selected from H, tert-butoxycarbonyl, C 1 -C 3 alkanoyl, (4-trifluoromethyl)benzoyl, N-phenylaminoacarbonyl, CH 2 R 8, wherein R 8 is selected from phenyl, benzo[d][1,3] dioxole, pyridin-3-yl, (pyrrolidin-1-yl)methyl, -CH 2 NHR 9 wherein R 9 is selected from H, C 1 -C 3 alkyl and cycloalkyl; R 2 is selected from the group consisting of -COOR 10 wherein R 10 is selected from H, C 1 -C 3 alkyl and cyclohexyl optionally substituted with at least one C 1 -C 3 alkyl group; -OH; -CONH 2; CN -tetrazol-5-yl or 1-(C 1 -C 3 alkyl)tetrazol-5-yl, -5-(C 1 -C 3 alkyl)1,2,4 triazol-3-yl, -5-(C 1 -C 3 alkyl) 1,2,4- oxadiazol-3yl, -5-(C 1 -C 3 alkyl) 1,3,4-oxadiazol-2-yl; R 3 is selected from F or H, R 4 is selected from H, CH 3, halogen, dimethylamino, pyridin-4yl, phenyl, 2- or 4- (halo)penyl, 2- or 4-(trifluoromethyl)phenyl and 2- and/or 4-halobenzyloxyfor use in the prevention and/or treatment of a disease associated with the activity of TRPM8 selected from the group consisting of pain, itch, cold-induced respiratory disorders, ischaemia, painful bladder syndrome, interstitial cystitis, detrusor overactivity, urinary incontinence, neurogenic detrusor overactivity, idiopathic detrusor overactivity, benign prostatic hyperplasia, stroke, neurodegeneration and psychiatric disorders. X is selected from S or O; R 1 is selected from the group consisting of: -OR 5 wherein R 5 is selected from H; C 1 -C 4 alkyl, trifluoromethanesulfonyl, benzyl, (trifluoromethyl)benzyl, (halo)benzyl, (trifluoromethyl)benzoyl, N-benzylcarbamoyl, cyclohexyloxyacetoyl substituted with at least one C 1 -C 3 alkyl group, (C 1 -C 3 alkoxy)methyl, C 1 -C 3 alkanoyl and CH 2 CH 2 NHR 6, wherein R 6 is selected from H and (furan-2-yl)methyl; -NHR 7 wherein R 7 is selected from H, tert-butoxycarbonyl, C 1 -C 3 alkanoyl, (4-trifluoromethyl)benzoyl, N-phenylaminoacarbonyl, CH 2 R 8, wherein R 8 is selected from phenyl, benzo[d][1,3] dioxole, pyridin-3-yl, (pyrrolidin-1-yl)methyl, -CH 2 NHR 9 wherein R 9 is selected from H, C 1 -C 3 alkyl and cycloalkyl; -OR 5 wherein R 5 is selected from H; C 1 -C 4 alkyl, trifluoromethanesulfonyl, benzyl, (trifluoromethyl)benzyl, (halo)benzyl, (trifluoromethyl)benzoyl, N-benzylcarbamoyl, cyclohexyloxyacetoyl substituted with at least one C 1 -C 3 alkyl group, (C 1 -C 3 alkoxy)methyl, C 1 -C 3 alkanoyl and CH 2 CH 2 NHR 6, wherein R 6 is selected from H and (furan-2-yl)methyl; R 6 is selected from H and (furan-2-yl)methyl; -NHR 7 wherein R 7 is selected from H, tert-butoxycarbonyl, C 1 -C 3 alkanoyl, (4-trifluoromethyl)benzoyl, N-phenylaminoacarbonyl, CH 2 R 8, wherein R 8 is selected from phenyl, benzo[d][1,3] dioxole, pyridin-3-yl, (pyrrolidin-1-yl)methyl, -CH 2 NHR 9 wherein R 9 is selected from H, C 1 -C 3 alkyl and cycloalkyl; R 8 is selected from phenyl, benzo[d][1,3] dioxole, pyridin-3-yl, (pyrrolidin-1-yl)methyl, -CH 2 NHR 9 wherein R 9 is selected from H, C 1 -C 3 alkyl and cycloalkyl; R 9 is selected from H, C 1 -C 3 alkyl and cycloalkyl; R 2 is selected from the group consisting of -COOR 10 wherein R 10 is selected from H, C 1 -C 3 alkyl and cyclohexyl optionally substituted with at least one C 1 -C 3 alkyl group; -OH; -CONH 2; CN -tetrazol-5-yl or 1-(C 1 -C 3 alkyl)tetrazol-5-yl, -5-(C 1 -C 3 alkyl)1,2,4 triazol-3-yl, -5-(C 1 -C 3 alkyl) 1,2,4- oxadiazol-3yl, -5-(C 1 -C 3 alkyl) 1,3,4-oxadiazol-2-yl; R 10 is selected from H, C 1 -C 3 alkyl and cyclohexyl optionally substituted with at least one C 1 -C 3 alkyl group; R 3 is selected from F or H, R 4 is selected from H, CH 3, halogen, dimethylamino, pyridin-4yl, phenyl, 2- or 4- (halo)penyl, 2- or 4-(trifluoromethyl)phenyl and 2- and/or 4-halobenzyloxyfor use in the prevention and/or treatment of a disease associated with the activity of TRPM8 selected from the group consisting of pain, itch, cold-induced respiratory disorders, ischaemia, painful bladder syndrome, interstitial cystitis, detrusor overactivity, urinary incontinence, neurogenic detrusor overactivity, idiopathic detrusor overactivity, benign prostatic hyperplasia, stroke, neurodegeneration and psychiatric disorders.